New York, New York, August 4, 2026
Nuvation Bio has announced that it will present new subgroup analyses from its pivotal Phase 2 TRUST-I and TRUST-II clinical trials evaluating IBTROZI® (taletrectinib) for the treatment of advanced ROS1-positive non-small cell lung cancer (ROS1+ NSCLC) at the IASLC 2026 World Conference on Lung Cancer (WCLC) and the European Society for Medical Oncology (ESMO) Annual Congress 2026. The analyses will examine the long-term efficacy and safety of IBTROZI across key patient subgroups, including patients previously treated with earlier-generation ROS1 inhibitors. The presentations are expected to reinforce the clinical profile of IBTROZI, a next-generation ROS1 inhibitor that received U.S. FDA approval in 2025 for adults with locally advanced or metastatic ROS1-positive NSCLC. The upcoming data will provide oncologists with additional insights into treatment consistency across diverse patient populations while supporting the therapy’s growing role in precision oncology and targeted lung cancer treatment.
Long-Term TRUST Studies Reinforce Clinical Benefits Across Patient Groups
The new analyses are based on long-term follow-up from the TRUST-I and TRUST-II Phase 2 studies, which continue to evaluate the efficacy and safety of IBTROZI (taletrectinib) in adults with advanced ROS1-positive NSCLC. According to Nuvation Bio, the subgroup analyses will assess whether the durable clinical benefits observed in the pivotal studies remain consistent across clinically important patient populations, including those who have previously received first-generation ROS1-targeted therapies. Company leadership emphasized that physicians require confidence that targeted therapies can deliver meaningful and sustained clinical benefit regardless of prior treatment history. The presentations scheduled for WCLC in Seoul, South Korea, and ESMO in Madrid, Spain, will highlight the therapy’s potential to become a standard-of-care treatment across multiple lines of therapy for patients with advanced ROS1-driven lung cancer. These findings are expected to provide clinicians with valuable evidence supporting treatment decision-making in an increasingly personalized oncology landscape.
IBTROZI Advances Precision Oncology in ROS1-Positive NSCLC
IBTROZI is an oral, central nervous system (CNS)-active, selective next-generation ROS1 inhibitor developed to address the treatment challenges associated with ROS1-positive metastatic non-small cell lung cancer, including disease progression within the brain. Approximately 2% of patients diagnosed with NSCLC harbor ROS1 gene rearrangements, while a substantial proportion of patients develop brain metastases during the course of their disease. The TRUST clinical development program includes multiple registrational studies evaluating the therapy across both advanced and early-stage disease. TRUST-I and TRUST-II have investigated IBTROZI in China and global patient populations, while TRUST-IV, an ongoing Phase 3 placebo-controlled study, is evaluating the therapy in patients with resected early-stage ROS1-positive NSCLC. In parallel, TRUST-III, a randomized confirmatory Phase 3 study, continues to compare IBTROZI with crizotinib in treatment-naïve patients. These studies collectively support Nuvation Bio’s strategy to expand the clinical application of targeted ROS1 inhibition across multiple disease settings.
Advertisement
Global Scientific Presentations Strengthen Oncology Development Strategy
The upcoming presentations underscore Nuvation Bio’s commitment to advancing precision oncology through robust clinical evidence and targeted drug development. As the oncology community continues seeking therapies capable of delivering durable responses while effectively controlling central nervous system disease, next-generation targeted inhibitors such as IBTROZI are becoming increasingly important within personalized cancer treatment. The company believes that demonstrating consistent long-term efficacy across diverse patient subgroups will further support physician confidence and optimize treatment selection for patients with advanced ROS1-positive NSCLC. By presenting new analyses at two of the world’s leading oncology congresses, Nuvation Bio continues to strengthen the scientific foundation supporting IBTROZI while reinforcing its broader mission of developing innovative therapies that address difficult-to-treat cancers through precision medicine. The expanded clinical evidence is expected to contribute to ongoing discussions regarding optimal sequencing of ROS1-targeted therapies and future standards of care in advanced lung cancer management.
Source: Nuvation Bio press release
